Clinical research summary – Gut-Brain

Synbiotic 2000 and Immune Modulation in ADHD – A Randomized Controlled Trial
Nutrients (2023), this double-blind randomized controlled trial conducted in Stockholm investigated the effects of Synbiotic 2000 on immune markers and short-chain fatty acids (SCFAs) in children and adults with ADHD. Among 248 participants, Synbiotic 2000 significantly reduced pro-inflammatory markers such as IL-12/IL-23p40 and suggestively lowered sICAM-1 in children, particularly those on ADHD medication. The treatment also increased propionic acid levels, which correlated with reduced vascular inflammation. These findings suggest Synbiotic 2000 may help modulate immune activity and improve inflammatory profiles in pediatric ADHD, highlighting the potential of dietary synbiotics as a complementary intervention. Further research is needed to confirm these effects in broader populations. Read more here

Synbiotic 2000 and Neuropsychiatric Function in ADHD – A Randomized Controlled Trial
Brain, Behavior, and Immunity (2020), this double-blind, placebo-controlled trial conducted at Karolinska Institutet investigated the effects of Synbiotic 2000 on symptoms and daily functioning in children and adults with ADHD. Over a 9-week period, 182 participants were randomized to receive either Synbiotic 2000 or placebo. While no overall effect on core ADHD symptoms was observed, subgroup analyses revealed that children with elevated baseline inflammation (measured by sVCAM-1) experienced reductions in autistic traits—particularly restricted and repetitive behaviors—when treated with Synbiotic 2000. Adults with similarly elevated inflammatory markers also showed improvements in emotion regulation. These findings suggest that synbiotic supplementation may benefit ADHD subgroups with heightened inflammatory profiles, warranting further research in larger, stratified samples. Read more here

Synbiotic 2000 in Adults with ADHD and/or BPD and Irritability – A Multicenter Randomized Controlled Trial
Brain, Behavior, and Immunity (2024), this multicenter double-blind randomized placebo-controlled trial assessed the efficacy of Synbiotic 2000 in managing irritability and associated symptoms in adults diagnosed with ADHD and/or Borderline Personality Disorder (BPD). Conducted across clinical centers in Hungary, Spain, and Germany, the 10-week study enrolled 180 adults with high irritability. Results showed that Synbiotic 2000 was well tolerated and led to a significantly greater improvement in irritability compared to placebo. Additional benefits were suggested for emotional dysregulation, inattention, emotional symptoms, perceived stress, and daily functioning. These findings provide preliminary evidence supporting the potential of synbiotic supplementation as a safe and adjunctive therapeutic option for emotionally dysregulated adults with ADHD and/or BPD, warranting further validation in larger cohorts. Read more here